Background
Sever al lines of evidence suggest that glycemic control in the hospital setting may be associated with improved outcomes. Funary and colleagues [1] [2] [3] [4] [5] [6] [7] [8] [9] have reported that outcomes in coronary artery bypass graft (CABG) recipients are affected by glycemic control, especially for the 3 days following the procedure. Specifically, 72 h of glycemic control is associated with reduced sternal wound infections and hospital mortality by more than half and length of stay by approximately 30% compared to historic controls, essentially eliminating the increased risk for mortality previously seen in patients with diabetes mellitus compared to those without diabetes mellitus. In the current hospital environment, most patients admitted to a cardiothoracic intensive care unit (ICU) do not stay for this critical 72 h. The average length of stay at the Cleveland Clinic cardiovascular intensive care unit (CVICU) is between 24 and 26 h before patients are transferred to a regular nursing floor.
There are several published and unpublished regimens for intensive glycemic control in the ICU. The Cleveland Clinic has had an insulin infusion protocol in the CVICU for more than 10 years. This protocol was developed in conjunction with CV anesthesiology (who are responsible for the metabolic and physiologic aspects of postoperative care), endocrinology, and nursing. However, approaches for transition of insulin orders as part of patient care to a regular nursing floor (RNF) have been less well characterized. Schmeltz and associates 10 and Bode and coworkers 11 each suggested 80% of the daily calculated requirement (based on the final 6 h of the infusion rate). This clearly is an improvement over earlier approaches of subcutaneous (SC) "coverage" insulin or "sliding scale." The sliding scale insulin approach fails to consider the need for basal insulin in most patients. Thus coverage is associated with wide variations in blood glucose as well as risks for hyperglycemia and hypoglycemia. Concerns for risk of hypoglycemia during the transition of care (i.e., the change in care from an ICU team to an RNF team) have led to the coverage insulin approach even in many hospitals where intravenous (IV) insulin is used in the ICU. One of the significant concerns about the use of basal insulin is the perceived risk for hypoglycemia. In an effort to facilitate one step in this transition from the ICU to the RNF, we recently implemented an insulin conversion protocol for postoperative cardiac surgical patients on IV insulin in the ICU to transition to basal SC insulin at the time of transfer to the RNF.
The purpose of this evaluation was to determine the safety and efficacy of the insulin glargine protocol in postoperative cardiac surgical patients transitioning from the CVICU to the RNF. Ninety-nine patients who received insulin infusions in the CVICU after cardiac surgery and were transferred to RNF in a timely fashion (within 72 h of surgery) between December 1 and December 31, 2007, provided the basis for this analysis.
Methods

Insulin Infusion and Subcutaneous Insulin Transition Protocols
Surgical patients undergoing a CABG, valve replacement/ repairs, or aortic repair/replacement were given lactated Ringer's solution for maintenance fluids intraoperatively and D5-0.2NS in the CVICU. If blood glucose levels are ≥150 mg/dl on two assessments within 1 h during surgery, an IV infusion of regular insulin is initiated and continued in the CVICU. Hyperglycemia is identified by hourly assessments of glucose as well as electrolytes and arterial blood gases intraoperatively. Similar assessments are made at least every 4 h during the CVICU stay and more frequently if glucose exceeds 110 mg/dl. If an insulin infusion is active, glucose is assessed hourly until stable and then assessed every 2 h. For some patients, the insulin infusion protocol is implemented postoperatively, using the same criteria. If blood glucose reaches a level of 150 mg/dl, a nurse-driven insulin infusion protocol (see Appendix) similar to that described by Osburne and colleagues 12 is initiated with a blood glucose target at or below 120 mg/dl. If the blood glucose reaches 80 mg/dl, the infusion is halted and restarted only if the threshold of 150 mg/dl is again reached. On the day of transfer from the CVICU to the RNF, an insulin glargine dose is calculated, extrapolating from the average IV regular insulin dose infused during the previous 8 h. The SC glargine dose (U) is calculated as the total amount of IV regular insulin received in the previous 8 h (U) multiplied by 3 and then divided by 2. If the patient received less than 8 h of IV regular insulin prior to planned transfer from the ICU, the single glargine dose would be half of the calculated amortized dose and is given 2 h before discontinuing the insulin infusion. In addition to the SC injection of insulin glargine, a sliding scale of rapid-acting insulin is used in a supplemental fashion that was generally proportional to the glargine dose. Most patients were not eating much at this time, so meal coverage was not prescribed.
Insulin glargine is administered in the CVICU 2 h prior to discontinuation of IV insulin infusion in anticipation of transfer. The original protocol specified a maximal protocol dose of 30 U of insulin glargine, unless higher doses were approved by the treating physician. Override of this upper dose limit varied with providers as did the comfort in ordering more insulin for those patients who needed higher insulin infusion rates. Generally, when ordered by the endocrinology service, the full calculated dose was administered, but this was less likely when ordered by nonendocrine providers. Upon arrival to the RNF, 4 point of care (POC) blood glucose measurements are obtained at 6 h intervals until the patient begins eating, and the endocrinology service is consulted, if not already on the case, for further management. Once a patient begins to eat, the timing of POC testing was changed to before each meal and at bedtime, and shortacting insulin was prescribed to address meal coverage as well as a supplemental scale to address inadequate coverage.
Study Design
The Cleveland Clinic Foundation institutional review board approved a prospective design to examine data from all postoperative patients ≥18 years old who had undergone a CABG, aortic surgery, or valve replacement/ repair requiring insulin infusion in the CVICU (five separate ICUs for a 1 month period, December 1 through December 31, 2007). Data were collected using concurrent noninterventional medical record review using medication administration records and electronic medication record system pharmacy records. Patient selection included diabetes and nondiabetes patients but excluded patients who were readmitted from RNFs for complications or patients who required CVICU stays longer than 7 days. Data collection involved de-identified information on demographics, diabetes mellitus history (if known, whether type 1 or type 2, and if type 2, whether or not previously treated with insulin), hemoglobin A1c, date and type of cardiac surgery (CABG initial or redo, aortic or valvular surgery or combination), catecholamine use in the CVICU (epinephrine, norepinephrine, or none) from a CV anesthesia database. Data were collected for the total amount of regular insulin received by IV infusion in the previous 8 h as well as the date and time insulin infusion started and discontinued from pharmacy records. Providers ordered the glargine dose (U), but the pharmacy calculated dose based on a review of the actual IV insulin required, and these were compared. Point of care blood testing date, time, and value (mg/dl) were collected. Primary assessment was the incidence of hypoglycemia (≤70 mg/dl) and hyperglycemia (≥150 mg/dl) with the insulin transfer protocol with a single value for either leading to those classifications. Secondary assessments were performed to assess blood glucose control using the calculated dose appropriate for diabetes patients as well as those without diabetes and postoperative hyperglycemic patients and to evaluate whether infusion with epinephrine or norepinephrine was administered during the 8 h insulin infusion period used to calculate the glargine dose influenced the appropriateness of the dosing.
Analysis
Data were evaluated using descriptive analysis for patient demographics, baseline characteristics, and the percentage of hypoglycemic and hyperglycemic patients on the insulin glargine protocol. Descriptive analysis was also utilized to analyze data on the patients who received pressors during the glargine dose calculation and those who received no pressor. Also analyzed was a comparison of appropriateness of the insulin glargine protocol in patients with a history of diabetes mellitus and those without known diabetes mellitus.
Statistics
Chi square were calculated for evidence of independence using the online calculator. In the situation of low numbers in a single cell, a Fisher's exact test was used.
Patient Subjects
All patients treated with IV insulin protocol post CV surgery in the CVICU in the month of December 2007 were included in this assessment of the transition protocol that had been used for at least 1 year prior. The subjects were identified by a confidential study number, and patient identifiers were not entered into the database system. The data were stored and secured in a nonshared hard drive database with a passwordprotected system that was only accessible to the principal and coprincipal investigators. Data collection forms were kept in a locked, secured cabinet, in which access to the data was limited to the investigators during the data collection period. At the conclusion of data analysis, data collection sheets were destroyed and de-identified information will be maintained in the database system for approximately 6 years per Health Insurance Portability and Accountability Act regulations.
Results
There were 99 consecutive patients who were treated with this protocol. The demographic and surgical features of the patients are summarized in Table 1 . Mean (± standard deviation) age was 64 (+ 13), and 67% were male. Most patients did not have diabetes mellitus (n = 76). Of the 23 with previous history of diabetes, 21 had type 2 and 2 had type 1. The types of surgery are summarized in Table 1 , with the majority involving valve-related surgery (61), followed by valve only and valve surgery in conjunction with coronary bypass (20) and CABGs alone (18) . In the majority (76 of 99 patients in the study period), this was begun intraoperatively, while in 23, the insulin infusion was begun in the ICU after transfer from the operating room.
The insulin glargine doses divided by 20 U ranges are summarized in Table 2 . Insulin glargine doses for diabetes and nondiabetes subjects are shown in Table 3 . While 50% (12 of 24) of the diabetes patients required >20 U, only 23% (17 of 76) of the nondiabetes patients required >20 U (x 2 = 7.573, p < .01, Table 3 ). Evaluation of several factors associated with the glycemia status after the insulin glargine transition demonstrated that there was no relationship between transition in insulin dose and the risk for hypoglycemia, hyperglycemia, or euglycemia. Only one patient without a history of diabetes developed hypoglycemia (blood glucose 64 mg/dl) after receiving a moderate dose (24 U) of SC insulin. Figure 1 shows the relationship among in the actual dose administered (y axis) and the calculated dose that would have been administered if the protocol dose had been given exactly according to the formula (x axis). This figure shows that calculated doses were often higher than administered doses, reflecting the upper limit of 30 U that required physician override to be administered. Patients whose preoperative status was "no diabetes mellitus" were not statistically more likely to be euglycemic after the insulin glargine transition protocol than those with a preoperative diagnosis of "diabetes mellitus" (x 2 = 6.92, p > .1). Vasopressor use did not affect transition insulin dose (x 2 = 1.40, p > .1, Table 4 ) or the risk for hyperglycemia (x 2 = 0.1487 , p > .5 , Table 5 ).
Discussion
The information obtained from this observational study is notable for the following features. First, in spite of moderate doses of SC insulin at the time of transition, we found only 1 episode of hypoglycemia, which was mild and with no critical hypoglycemia values (>40 mg/dl). Second, relatively high doses of insulin, in many cases above the 30 U originally specified in the protocol, were required to achieve euglycemia. Hyperglycemia occurred most frequently in subjects whose proposed doses based on the protocol had lower doses given because of the ceiling standard protocol dose of 30 U being used because of safety concerns. We suspect that hyperglycemia would have been less frequent had higher doses based on the transition formula actually been allowed as reflected in Figure 1 . Third, most of the patients who received the transition protocol did not have previously diagnosed diabetes. Thus this treatment strategy should not be limited to patients with diabetes and can be given safely to patients without diabetes. Euglycemia was achieved more commonly in patients without a history of diabetes. Finally, the use of pressors in the CVICU did not have a significant effect on the transition insulin dose or the subsequent risk for hyperglycemia. Thus the transition protocol can be implemented equally effectively in patients who did or did not require pressors.
Unpublished observational data from the Cleveland Clinic obtained in the mid 1990s suggested that hyperglycemia in the immediate postoperative period was associated with increased risk for sternal wound infections in both diabetes and nondiabetes patients. On that basis, insulin infusion protocols were implemented as a quality measure. The seminal observations of Furnary and colleagues [1] [2] [3] [4] [5] [6] [7] [8] have demonstrated that the prevention of hyperglycemia during the first 72 h following cardiac surgery is associated with a 63% reduction in deep sternal wound infections, a 65% reduction in hospital mortality, and a 30% reduction in hospital length of stay. Other lines of evidence supporting the concept that glycemic control and/or insulin therapy to improve outcomes in ICU patients include the large trial by Van den Berghe and associates [13] [14] [15] [16] [17] in Europe. She confirmed that strict glycemic control improved morbidity outcomes in diabetes and nondiabetes patients with elevated glucose in an surgical intensive care unit (SICU) population that included a large percentage of cardiac surgery patients.
Postoperative hyperglycemia, defined as plasma glucose levels ≥200 mg/dl, is a common metabolic manifestation of operative and postoperative patient stress. 1 High blood glucose levels caused by this stress have been shown to be a risk factor for increased morbidity and mortality among surgical patients, resulting in complications such as impaired wound healing, severe infections, polyneuropathy, and multiple organ failure. Postoperative hyperglycemia characterized by increased glucose production and suppressed insulin secretion is felt to be caused by the excessive release of counter-regulatory hormones such as glucagon, epinephrine, norepinephrine, and glucocorticoids, as well as the overproduction of the cytokines (inflammatory mediators) TNF-α, IL-1, and IL-6.
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While the meta-analyses by Weiner and coworkers 19 and Pittas and colleagues 20 bring into question the most appropriate glycemic target, the risk for infectious complications in surgical patients is a confirmed benefit of tighter glucose control.
The treatment for hyperglycemia has encompassed various types of insulin regimens based on individual pharmacodynamic characteristics. Historically, treatment for postoperative hyperglycemia was SC sliding scale regular insulin. However, Gearhart and colleagues 21 demonstrated ineffective glycemic control with the short-acting sliding scale resulting in wide fluctuations in blood glucose values, high glucose concentrations despite treatment, and longer treatment periods. Although regular insulin may have a relatively rapid onset of action with a peak concentration at 2 to 4 h, it requires frequent dosing with a short duration of action of only 6 to 8 h.
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Insulin neutral protamine Hagedorn (NPH) and insulin glargine have each been utilized in the treatment of postoperative hyperglycemia. Insulin NPH, an intermediate-acting insulin, exhibits a duration of action longer than regular insulin but shorter than glargine. In comparison to four times daily dosing with regular insulin, NPH can be dosed twice daily with a peak effect at 4-6 h and a duration of 12-16 h. [21] [22] [23] It is the peak that makes this insulin less than ideal for the purpose of transition from an insulin infusion.
Insulin glargine is a long-acting insulin analogue that has biologic activity similar to human insulin in stimulating glucose uptake by the adipose and skeletal muscle tissues and importantly in inhibiting hepatic glucose production. 24 The pharmacokinetic profile of insulin glargine that distinguishes it from other types of insulin is its average duration of about 24 h, and its relative lack of a peak produces a profile ideal for basal insulin that provides the anticatabolic actions of basal insulin. Insulin glargine exists as an acidic solution with a pH of 4 that is neutralized in the SC tissue upon injection, promoting the development of microprecipitates. The microprecipitates slowly release small amounts of insulin into the circulation, exhibiting a constant concentration of insulin over a 24 h period, mimicking a continuous infusion of regular insulin. [22] [23] [24] With little peak in concentration and a 24 h duration of action, insulin glargine offers a convenient, once-daily dosing. [22] [23] [24] A study conducted by Yeldandi and colleagues 23 compared once-daily insulin glargine to twice-daily NPH/regular insulin in postoperative CV surgical patients undergoing a CABG or valve replacement/repair transitioning from the SICU to the RNF. All patients with postoperative glucose values above the goal of 100 to 140 mg/dl were initiated on an IV insulin infusion. Prior to transfer from the SICU to the RNF, patients were randomized to receive either once-daily insulin glargine or twice-daily insulin NPH/regular. The initial glargine and NPH/regular insulin doses were calculated based on the last stable IV infusion rate, and the IV and SC insulin regimens were overlapped for 1 to 2 h prior to discontinuing the IV infusion. On the RNF, insulin glargine demonstrated similar glycemic control in the nondiabetes group (p = .065) but significantly higher mean blood glucose levels in the diabetes group (p = .016) compared to the NPH/regular regimen. However, the incidence of hypoglycemia was significantly lower with insulin glargine than NPH/regular in both subjects with diabetes and those without (p = .036).
The importance of avoidance of hypoglycemia seen in the Cleveland Clinic approach should not be overlooked. The findings of Gandhi and associates 25 show no benefit and greater mortality with intensively treated cardiac surgery patients. The SUGAR-NICE study, 26 managing a more heterogeneous group of critically ill patients, failed to show benefit of more intensive glucose control. Each of these may be explained by the higher incidence of hypoglycemia seen in the intensive groups of each study. The volume of patients submitted to this protocol is seen in as few as 100 or more studies, where such subjects are managed for hyperglycemia after CV surgery each month. That is more than the total subjects in the trial of Gandhi and coworkers. 25 Only Van den Berghe 13-17 has a comparable volume of subjects managed in a uniform fashion at a single center.
In summary, we offer a protocol for conversion from IV regular insulin infusion given in the ICU to a SC basal insulin regime that is quite safe and effective. Our study shows that the approach to substituting 50% of the previous 24 h calculated daily need of insulin glargine is not associated with a significant risk for hypoglycemia and should allay such fears. The use of the full calculated dose would likely have improved the efficacy further and would unlikely have reduced the safety of this protocol.
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